Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Hongqi Pharmaceutical's 0.3g Isoniazid Tablets passed the consistency evaluation of generic drugs
Category:
Company News
Author:
Source:
Add time:2020-02-06 13:32
On July 16, 2019, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharmaceutical") issued an announcement that its holding subsidiary Shenyang Hongqi Pharmaceutical Co., Ltd. ("Hongqi Pharmaceutical") received the National Drug Administration The "Approval for Supplementary Drug Application" (Lot Number: 2019B03243) on Isoniazid Tablets (Specification: 0.3g) issued by the Bureau, the drug passed the consistency evaluation of generic drugs.
The announcement shows that isoniazid tablets are mainly used in combination with other anti-tuberculosis drugs and are suitable for the treatment of various types of tuberculosis. In March 2019, Hongqi Pharmaceutical's isoniazid tablets (specification: 0.1g) passed the consistency evaluation of generic drugs. In 2018, the sales of Shenyang Hongqi Isoniazid Tablets (specification: 0.1g) in China (excluding Hong Kong, Macao and Taiwan regions, the same below) were approximately RMB 29.09 million (unaudited) and Isoniazid Tablets (specification: 0.3) g) No sales. According to the latest data from IQVIA CHPA, in 2018, the sales of isoniazid tablets in China were approximately RMB 94.36 million.
As of June 2019, Fosun Pharma (that is, Fosun Pharma and its holding subsidiary Hongqi Pharmaceutical) has invested approximately RMB 5.63 million in R&D for the consistency evaluation of isoniazid tablets (including 0.1g and 0.3g specifications). Audited).
At present, Hongqi Pharmaceutical has passed the consistency evaluation of generic drugs in 3 varieties and 5 specifications. They are pyrazinamide tablets (specifications: 0.25g, 0.5g), 0.3g rifampicin capsules, and isoniazid tablets (specifications). : 0.1g, 0.3g). As a subsidiary of Fosun Pharmaceuticals, Hongqi Pharmaceuticals has always taken independent innovation as the driving force for corporate development, and continued to improve the drug R&D and innovation system of “combination of imitation and innovation”. At the same time, it has been conducting drug consistency studies in strict accordance with national requirements to improve drug performance. Safety and effectiveness, to ensure the safety and effectiveness of drugs used by the people, and to help the country achieve the goal of ending tuberculosis by 2035 as soon as possible.
